Skip to main content

Table 4 Proportion of symptomatic TEs according to the type of chemotherapy regimen

From: Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

 

% (n/N)

(95% CI)

Thromboembolic events

Nadroparin

Placebo

Relative risk

Overall PROTECHT population

2 (15/769)

3.9 (15/381)

0.5 (0.24-1.00)

Chemotherapy regimen containing:

   

   5-Fluorouracil

2.5 (7/285)

3.3 (5/151)

0.74 (0.24-2.30)

   Cisplatin

2.3 (4/177)

7.0 (6/86)

0.32 (0.09-1.12)

   Gemcitabine

2.6 (4/156)

8.1 (7/86)

0.32 (0.09-1.05)

   Oxaliplatin

0.7 (1/143)

1.1 (1/89)

0.62 (0.04-9.83)

   Docetaxel

1.4 (2/142)

4.5 (3/67)

0.31 (0.05-1.84)

   Carboplatin

0.8 (1/119)

5.5 (3/55)

0.15 (0.02-1.45)

   Epirubicin

0.0 (0/54)

8.3 (2/24)

ND

   Adriamycin

0.0 (0/25)

5.3 (1/19)

ND

   Irinotecan

3.1 (3/96)

0.0 (0/41)

ND

   Vinca alkaloids

2.2 (2/90)

3.7 (1/27)

0.60 (0.06-6.36)

   Capecitabine

0.0 (0/61)

3.3 (1/30)

ND

   Etoposide

2.4 (1/41)

11.8 (2/17)

0.21 (0.02-2.14)

   Cyclophosphamide

0.0 (0/33)

5.6 (1/18)

ND

Previous Chemotherapy

   

   Naïve

2.5 (10/405)

5.2 (11/213)

0.48 (0.21-1.11)

   Non-naïve

1.4 (5/364)

2.4 (4/168)

0.58 (0.16-2.12)

  1. No TE events were observed among patients receiving trastuzumab, cetuximab, bevacizumab, liposomal doxorubicin or mitomycin. Abbreviation: ND, not determinable.